Holzer Holzer & Fistel, LLC Announces Investigation Into Potential Claims For Breaches Of Fiduciary Duty By Certain Officers And Directors Of ZELTIQ Aesthetics, Inc.

Holzer Holzer & Fistel, LLC announces that it is investigating potential breaches of fiduciary duty by certain officers and directors of ZELTIQ Aesthetics, Inc. (“ZELTIQ” or the “Company”) (NYSE: ZLTQ). On March 13, 2012, a class action lawsuit was filed in the Superior Court of Alameda County, California alleging that ZELTIQ violated the federal securities laws in connection with its initial public offering (“IPO”) completed on October 24, 2011. The lawsuit alleges, among other things, that ZELTIQ omitted material information from its IPO documents regarding known disruptions in Company sales and increasing competition.

The firm’s investigation seeks to determine if the allegations contained in the class action complaint also give rise to the separate claims against the Board of Directors for breaches of fiduciary duty, which could be enforced on behalf of the Company through shareholder derivative litigation.

If you have continuously held ZELTIQ shares since 2011 and would like to discuss your legal rights, you may contact Michael I. Fistel, Jr., Esq. or Marshall P. Dees, Esq. via email at mfistel@holzerlaw.com, or mdees@holzerlaw.com, or via toll-free telephone at (888) 508-6832.

Holzer Holzer & Fistel, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.

Copyright Business Wire 2010

If you liked this article you might like

2 Small Biotechs Under $5 May Be Bargains

Small-Cap Turnaround Stories

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value